Lithium chloride antileukemic activity in acute promyelocytic leukemia is GSK-3 and MEK/ERK dependent

[1]  Stephen L. Abrams,et al.  Multifaceted roles of GSK-3 and Wnt/β-catenin in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention , 2013, Leukemia.

[2]  Paola Fazi,et al.  Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. , 2013, The New England journal of medicine.

[3]  C. Chomienne,et al.  Regulation of the transcriptional activity of nuclear receptors by the MEK/ERK1/2 pathway. , 2012, Cellular signalling.

[4]  P. S. Klein,et al.  Maintenance of Hematopoietic Stem Cells through Regulation of Wnt and mTOR Pathways , 2012, Nature Medicine.

[5]  Barry P. Young,et al.  The Mck1 GSK-3 kinase inhibits the activity of Clb2-Cdk1 post-nuclear division , 2012, Cell cycle.

[6]  Gabriela Alexe,et al.  The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia. , 2012, The Journal of clinical investigation.

[7]  L. Sun,et al.  GSK3 is a regulator of RAR-mediated differentiation , 2012, Leukemia.

[8]  H. de Thé,et al.  Curing APL through PML/RARA degradation by As2O3. , 2012, Trends in molecular medicine.

[9]  S. Collins,et al.  GSK3 inhibitors enhance retinoic acid receptor activity and induce the differentiation of retinoic acid-sensitive myeloid leukemia cells , 2011, Leukemia.

[10]  P. Fenaux,et al.  New Role for Granulocyte Colony-Stimulating Factor-Induced Extracellular Signal-Regulated Kinase 1/2 in Histone Modification and Retinoic Acid Receptor α Recruitment to Gene Promoters: Relevance to Acute Promyelocytic Leukemia Cell Differentiation , 2011, Molecular and Cellular Biology.

[11]  Robert Lindeman,et al.  Glycogen synthase kinase--3β inhibitors suppress leukemia cell growth. , 2010, Experimental hematology.

[12]  F. Fornai,et al.  Intracellular pathways underlying the effects of lithium , 2010, Behavioural pharmacology.

[13]  Kevin S. Smith,et al.  GSK-3 promotes conditional association of CREB and its coactivators with MEIS1 to facilitate HOX-mediated transcription and oncogenesis. , 2010, Cancer cell.

[14]  H. Stunnenberg,et al.  PML-RARalpha/RXR Alters the Epigenetic Landscape in Acute Promyelocytic Leukemia. , 2010, Cancer cell.

[15]  H. Dombret,et al.  PML–RARα ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL , 2010, Leukemia.

[16]  H. Dombret,et al.  Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. , 2009, Blood.

[17]  S. Lalevée,et al.  Phosphorylation control of nuclear receptors. , 2010, Methods in molecular biology.

[18]  W. Tong,et al.  Pivotal role for glycogen synthase kinase-3 in hematopoietic stem cell homeostasis in mice. , 2009, The Journal of clinical investigation.

[19]  H. Dombret,et al.  When can real-time quantitative RT-PCR effectively define molecular relapse in acute promyelocytic leukemia patients? (Results of the French Belgian Swiss APL Group). , 2009, Leukemia research.

[20]  I. Weissman,et al.  Glycogen synthase kinase 3β missplicing contributes to leukemia stem cell generation , 2009, Proceedings of the National Academy of Sciences.

[21]  Jia Luo,et al.  Glycogen synthase kinase 3beta (GSK3beta) in tumorigenesis and cancer chemotherapy. , 2009, Cancer letters.

[22]  Carlos A. Garcia,et al.  Toll-Like Receptor-Mediated Production of IL-1Ra Is Negatively Regulated by GSK3 via the MAPK ERK1/21 , 2009, The Journal of Immunology.

[23]  Cécile Rochette-Egly,et al.  Dynamic and combinatorial control of gene expression by nuclear retinoic acid receptors (RARs) , 2009, Nuclear receptor signaling.

[24]  Mark J. Murphy,et al.  Glycogen synthase kinase 3 in MLL leukaemia maintenance and targeted therapy , 2008, Nature.

[25]  L. Robb,et al.  Cytokine receptors and hematopoietic differentiation , 2007, Oncogene.

[26]  Jiang-Ning Zhou,et al.  Lithium regulates hippocampal neurogenesis by ERK pathway and facilitates recovery of spatial learning and memory in rats after transient global cerebral ischemia , 2007, Neuropharmacology.

[27]  Daniel G. Tenen,et al.  Transcription factors in myeloid development: balancing differentiation with transformation , 2007, Nature Reviews Immunology.

[28]  R. Moon,et al.  Glycogen synthase kinase-3 is an in vivo regulator of hematopoietic stem cell repopulation , 2006, Nature Medicine.

[29]  A. Sartorelli,et al.  Analysis of the relationship between Scl transcription factor complex protein expression patterns and the effects of LiCl on ATRA-induced differentiation in blast cells from patients with acute myeloid leukemia. , 2004, Leukemia research.

[30]  H. Son,et al.  Lithium selectively increases neuronal differentiation of hippocampal neural progenitor cells both in vitro and in vivo , 2004, Journal of neurochemistry.

[31]  M. Robin,et al.  PML-RARA–targeted DNA vaccine induces protective immunity in a mouse model of leukemia , 2003, Nature Medicine.

[32]  B. Doble,et al.  GSK-3: tricks of the trade for a multi-tasking kinase , 2003, Journal of Cell Science.

[33]  D. Chuang,et al.  Chronic lithium treatment antagonizes glutamate-induced decrease of phosphorylated CREB in neurons via reducing protein phosphatase 1 and increasing MEK activities , 2003, Neuroscience.

[34]  A. Zeiher,et al.  Glycogen Synthase Kinase-3 Couples AKT-dependent Signaling to the Regulation of p21Cip1 Degradation* , 2002, The Journal of Biological Chemistry.

[35]  S. Chevret,et al.  In vitro all-trans retinoic acid sensitivity of acute promyelocytic leukemia blasts: a novel indicator of poor patient outcome. , 2001, Blood.

[36]  M. Koken,et al.  Retinoic Acid Induces Proteasome-Dependent Degradation of Retinoic Acid Receptor α (RARα) and Oncogenic RARα Fusion Proteins , 1999 .

[37]  S. Kogan,et al.  Retinoic Acid and Arsenic Synergize to Eradicate Leukemic Cells in a Mouse Model of Acute Promyelocytic Leukemia , 1999, The Journal of experimental medicine.

[38]  M. Koken,et al.  Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARalpha) and oncogenic RARalpha fusion proteins. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[39]  A. Sugawara,et al.  Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia. , 1998, Blood.

[40]  I. Weissman,et al.  A PMLRARα transgene initiates murine acute promyelocytic leukemia , 1997 .

[41]  I. Weissman,et al.  A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[42]  P. Cohen,et al.  Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B , 1995, Nature.

[43]  P. Fenaux,et al.  In vitro treatment with retinoids or the topoisomerase inhibitor, VP-16, evidences different functional apoptotic pathways in acute promyelocytic leukemic cells. , 1995, Leukemia.

[44]  P. Pandolfi,et al.  Acute promyelocytic leukemia: from genetics to treatment. , 1994, Blood.

[45]  P. Chambon,et al.  Mouse retinoic acid receptor alpha 2 isoform is transcribed from a promoter that contains a retinoic acid response element. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[46]  S. Collins,et al.  Retinoic acid-induced granulocytic differentiation of HL-60 myeloid leukemia cells is mediated directly through the retinoic acid receptor (RAR-alpha) , 1990, Molecular and cellular biology.